ifosfamide has been researched along with Emesis in 55 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy." | 9.27 | Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. ( Akagi, T; Bun, S; Fujiwara, Y; Hayashi, Y; Makino, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M, 2018) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 9.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| "Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 9.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 9.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| " In this study, 19 male and 13 female patients with osteosarcoma, ages 9 to 45 years, treated with chemotherapy, received intravenous tropisetron 5 mg plus dexamethasone 8 mg every 12 hours during the first two cycles of the preoperative treatment: cisplatin 120 mg/m2 over 48 hours followed by Adriamycin 75 mg/m2 delivered in 24 hours and continuous infusion of ifosfamide 15 g/m2 over 120 hours." | 9.10 | Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours. ( Bacci, G; Beghelli, C; Biolchini, A; Forni, C; Loro, L; Mazzei, T; Tremosini, M; Triggiani, A, 2003) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 9.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| " Further evaluations of this novel ifosfamide-epirubicin schedule are not warranted, even if the HD-IFO regimen could be taken forward specifically for leiomyosarcomas in a phase II trial." | 9.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "To compare the efficacy and safety of intravenously administered granisetron with those of chlorpromazine plus dexamethosone in the prevention of ifosmamide-induced emesis in children with malignant disease." | 9.08 | A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. ( Cedar, E; Hählen, K; Pinkerton, CR; Quintana, E, 1995) |
| "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent." | 7.69 | Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 7.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 7.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 7.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy." | 6.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 6.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy." | 5.27 | Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. ( Akagi, T; Bun, S; Fujiwara, Y; Hayashi, Y; Makino, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M, 2018) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 5.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| "Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 5.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 5.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| " In this study, 19 male and 13 female patients with osteosarcoma, ages 9 to 45 years, treated with chemotherapy, received intravenous tropisetron 5 mg plus dexamethasone 8 mg every 12 hours during the first two cycles of the preoperative treatment: cisplatin 120 mg/m2 over 48 hours followed by Adriamycin 75 mg/m2 delivered in 24 hours and continuous infusion of ifosfamide 15 g/m2 over 120 hours." | 5.10 | Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours. ( Bacci, G; Beghelli, C; Biolchini, A; Forni, C; Loro, L; Mazzei, T; Tremosini, M; Triggiani, A, 2003) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 5.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| " Further evaluations of this novel ifosfamide-epirubicin schedule are not warranted, even if the HD-IFO regimen could be taken forward specifically for leiomyosarcomas in a phase II trial." | 5.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "To compare the efficacy and safety of intravenously administered granisetron with those of chlorpromazine plus dexamethosone in the prevention of ifosmamide-induced emesis in children with malignant disease." | 5.08 | A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. ( Cedar, E; Hählen, K; Pinkerton, CR; Quintana, E, 1995) |
| "To examine the influence of the proposed symptom cluster of fatigue, nausea and vomiting, and sleep disturbances on clinical outcomes defined as behavior changes, depression, and performance status in children and adolescents before and after receiving cisplatin, doxorubicin, or ifosfamide chemotherapy." | 3.76 | Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; Krull, K; McCarthy, K; Sambuco, G, 2010) |
| "The aim of this study was to investigate the severity and time-course of alterations in gastroduodenal and intestinal permeability in relation to nausea/emesis following administration of the highly emetogenic polydrug regimen IFADIC (ifosfamide, Adriamycin, dacarbazine) using a differential lactulose/mannitol absorption (SLM) test." | 3.71 | Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). ( Brodowicz, T; Fazeny-Dörner, B; Marosi, C; Muhm, M; Veitl, M; Vogelsang, H; Wenzel, C; Zielinski, C, 2002) |
| "Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent." | 3.69 | Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 3.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 3.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 3.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| "To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL)." | 2.74 | [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. ( Cen, XN; Chen, H; Han, MZ; Han, XH; He, XH; Huang, H; Huang, HQ; Jiang, WQ; Liu, P; Ma, J; Ren, HY; Shen, XM; Shi, YK; Wang, C; Wang, JM; Yang, S; Zhou, SY; Zhu, J, 2009) |
| "A preliminary co-operative study by 7 institutes was conducted to determine the optimal dosage of the combination regimen with nedaplatin, bleomycin and ifosfamide, which is used in a phase III clinical study, to investigate its efficacy as neoadjuvant chemotherapy against advanced cervical cancer of the uterus." | 2.68 | [Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study]. ( Hatae, M; Hirabayashi, K; Kanazawa, K; Noda, K; Ozaki, M; Terashima, Y; Yakushiji, M, 1997) |
| "Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy." | 2.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| " The overall incidence of adverse experiences was significantly lower in the granisetron group (60." | 2.67 | The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. ( , 1993) |
| "Delayed emesis was observed after both platinum analogues but occurred more frequently and lasted longer after cisplatin." | 2.67 | Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. ( du Bois, A; Karck, U; Madjar, H; Meerpohl, HG; Prömpeler, H; Thomssen, C; Vach, W, 1994) |
| "Levels of depression were lower and showed little change." | 2.67 | A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. ( Bleehen, NM; Girling, DJ; Machin, D; Stephens, RJ, 1993) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 2.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1." | 2.40 | [Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer]. ( Asahi, T; Hata, K; Katayama, Y; Kobashi, K; Kobuke, M; Kondo, K; Kumon, H; Maki, Y; Nanba, K; Nasu, Y; Ochi, J; Ohashi, T; Ohmori, H; Ozaki, Y; Saegusa, M; Saika, T; Tanahashi, T; Tsushima, T; Uno, S; Yamashita, Y, 1998) |
| " The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide." | 1.32 | Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004) |
| "Ifosfamide chemotherapy was studied in 20 patients with advanced pancreatic carcinoma." | 1.30 | [Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma]. ( Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Suda, Y; Terashi, K; Yamamoto, K; Yamato, A, 1997) |
| "Emesis was characterized by expulsion of solid or liquid material." | 1.29 | Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents. ( Göthert, M; Herold, H; Szelenyi, I, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (25.45) | 18.7374 |
| 1990's | 20 (36.36) | 18.2507 |
| 2000's | 16 (29.09) | 29.6817 |
| 2010's | 5 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bun, S | 1 |
| Yonemori, K | 1 |
| Akagi, T | 1 |
| Noguchi, E | 1 |
| Shimoi, T | 1 |
| Shimomura, A | 1 |
| Yunokawa, M | 1 |
| Shimizu, C | 1 |
| Fujiwara, Y | 1 |
| Makino, Y | 1 |
| Hayashi, Y | 1 |
| Tamura, K | 1 |
| Xiao, Y | 1 |
| Liu, J | 1 |
| Liu, YC | 1 |
| Huang, XE | 1 |
| Guo, JX | 1 |
| Wei, W | 1 |
| Higgins, SC | 1 |
| Zakashansky, K | 1 |
| Bovbjerg, DH | 1 |
| Hagopian, G | 1 |
| Shiu, JR | 1 |
| Romanick, M | 1 |
| Stobart, K | 1 |
| Coriat, R | 1 |
| Mir, O | 1 |
| Camps, S | 1 |
| Ropert, S | 1 |
| Billemont, B | 1 |
| Leconte, M | 1 |
| Larousserie, F | 1 |
| Anract, P | 1 |
| Alexandre, J | 1 |
| Goldwasser, F | 1 |
| Shi, YK | 1 |
| Yang, S | 1 |
| Han, XH | 1 |
| Ma, J | 1 |
| Ren, HY | 1 |
| Cen, XN | 1 |
| Zhou, SY | 1 |
| Wang, C | 1 |
| Jiang, WQ | 1 |
| Huang, HQ | 1 |
| Wang, JM | 1 |
| Zhu, J | 1 |
| Chen, H | 1 |
| Han, MZ | 1 |
| Huang, H | 1 |
| Shen, XM | 1 |
| Liu, P | 1 |
| He, XH | 1 |
| Hockenberry, MJ | 1 |
| Hooke, MC | 1 |
| Gregurich, M | 1 |
| McCarthy, K | 1 |
| Sambuco, G | 1 |
| Krull, K | 1 |
| Jordan, K | 1 |
| Jahn, F | 1 |
| Jahn, P | 1 |
| Behlendorf, T | 1 |
| Stein, A | 1 |
| Ruessel, J | 1 |
| Kegel, T | 1 |
| Schmoll, HJ | 1 |
| Huang, YH | 1 |
| Wen, XP | 1 |
| Hu, L | 1 |
| Forni, C | 2 |
| Loro, L | 2 |
| Mazzei, T | 2 |
| Beghelli, C | 2 |
| Biolchini, A | 2 |
| Tremosini, M | 2 |
| Triggiani, A | 1 |
| Bacci, G | 2 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Kopp, HG | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Lorent, N | 1 |
| De Leyn, P | 1 |
| Lievens, Y | 1 |
| Verbeken, E | 1 |
| Nackaerts, K | 1 |
| Dooms, C | 1 |
| Van Raemdonck, D | 1 |
| Anrys, B | 1 |
| Vansteenkiste, J | 1 |
| Takenaka, M | 1 |
| Okamoto, Y | 1 |
| Ikeda, K | 1 |
| Hashimoto, R | 1 |
| Ueda, T | 1 |
| Kurokawa, N | 1 |
| Takagi, T | 1 |
| Uejima, E | 1 |
| Hartlapp, JH | 1 |
| Jaeger, N | 1 |
| Fischer, P | 1 |
| Weissbach, L | 1 |
| Costanzi, JJ | 2 |
| Morgan, LR | 2 |
| Hokanson, J | 1 |
| Holoye, PY | 2 |
| Anderson, T | 2 |
| Duelge, J | 2 |
| Hansen, RM | 2 |
| Ritch, PS | 2 |
| Harrison, EF | 1 |
| Hawke, JE | 1 |
| Hunter, HL | 1 |
| Plotkin, D | 1 |
| Tucker, WG | 1 |
| Worrall, PM | 1 |
| Higi, M | 1 |
| Niederle, N | 1 |
| Bierbaum, W | 1 |
| Schmidt, CG | 1 |
| Seeber, S | 1 |
| Bleehen, NM | 1 |
| Girling, DJ | 1 |
| Machin, D | 1 |
| Stephens, RJ | 1 |
| Hählen, K | 1 |
| Quintana, E | 1 |
| Pinkerton, CR | 1 |
| Cedar, E | 1 |
| Szelenyi, I | 1 |
| Herold, H | 1 |
| Göthert, M | 1 |
| du Bois, A | 2 |
| Vach, W | 2 |
| Thomssen, C | 1 |
| Karck, U | 1 |
| Madjar, H | 1 |
| Prömpeler, H | 1 |
| Meerpohl, HG | 1 |
| Cullen, MH | 2 |
| Graziano, SL | 1 |
| Herndon, JE | 1 |
| Richards, F | 1 |
| DiFino, S | 1 |
| Modeas, C | 1 |
| Duggan, DB | 1 |
| Green, MR | 1 |
| Hewitt, M | 1 |
| McQuade, B | 1 |
| Stevens, R | 1 |
| Markman, M | 1 |
| Kennedy, A | 1 |
| Webster, K | 1 |
| Kulp, B | 1 |
| Peterson, G | 1 |
| Belinson, J | 1 |
| Fujiki, T | 1 |
| Futatsuki, K | 1 |
| Akazawa, S | 1 |
| Yamamoto, K | 1 |
| Kanda, Y | 1 |
| Yamato, A | 1 |
| Terashi, K | 1 |
| Suda, Y | 1 |
| Siebert, C | 1 |
| Holy, R | 1 |
| Ledergerber, M | 1 |
| Wechsel, U | 1 |
| Kriesinger-Schroeder, H | 1 |
| Noda, K | 1 |
| Hirabayashi, K | 1 |
| Terashima, Y | 1 |
| Ozaki, M | 1 |
| Yakushiji, M | 1 |
| Hatae, M | 1 |
| Kanazawa, K | 1 |
| Pronzato, P | 1 |
| Vigani, A | 1 |
| Pensa, F | 1 |
| Vanoli, M | 1 |
| Tani, F | 1 |
| Vaira, F | 1 |
| Glisson, B | 1 |
| Lee, JS | 1 |
| Palmer, J | 1 |
| Fossella, F | 1 |
| Shin, DM | 1 |
| Murphy, WK | 1 |
| Perez-Soler, R | 1 |
| Hong, WK | 1 |
| Pronk, LC | 1 |
| Schrijvers, D | 1 |
| Schellens, JH | 1 |
| de Bruijn, EA | 1 |
| Planting, AS | 1 |
| Locci-Tonelli, D | 1 |
| Groult, V | 1 |
| Verweij, J | 1 |
| van Oosterom, AT | 1 |
| Maki, Y | 1 |
| Tsushima, T | 1 |
| Nasu, Y | 1 |
| Kumon, H | 1 |
| Ohmori, H | 1 |
| Tanahashi, T | 1 |
| Nanba, K | 1 |
| Ohashi, T | 1 |
| Kondo, K | 1 |
| Saika, T | 1 |
| Asahi, T | 1 |
| Saegusa, M | 1 |
| Ozaki, Y | 1 |
| Yamashita, Y | 1 |
| Katayama, Y | 1 |
| Kobuke, M | 1 |
| Uno, S | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Hata, K | 1 |
| Han, JY | 1 |
| Kim, HK | 1 |
| Choi, BG | 1 |
| Moon, H | 1 |
| Hong, YS | 1 |
| Lee, KS | 1 |
| Dodd, PM | 1 |
| McCaffrey, JA | 1 |
| Hilton, S | 1 |
| Mazumdar, M | 1 |
| Herr, H | 1 |
| Kelly, WK | 1 |
| Icasiano, E | 1 |
| Boyle, MG | 1 |
| Bajorin, DF | 1 |
| Ferrari, S | 1 |
| Simoni, P | 1 |
| Strazzari, S | 1 |
| Puggioli, C | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Serrone, L | 1 |
| Zeuli, M | 1 |
| Gamucci, T | 1 |
| Nardi, M | 1 |
| Cognetti, F | 1 |
| Fulda, S | 1 |
| Fichtner, I | 1 |
| Hero, B | 1 |
| Berthold, F | 1 |
| Edmonson, JH | 1 |
| Petersen, IA | 1 |
| Shives, TC | 1 |
| Mahoney, MR | 1 |
| Rock, MG | 1 |
| Haddock, MG | 1 |
| Sim, FH | 1 |
| Maples, WJ | 1 |
| O'Connor, MI | 1 |
| Gunderson, LL | 1 |
| Foo, ML | 1 |
| Pritchard, DJ | 1 |
| Buckner, JC | 1 |
| Stafford, SL | 1 |
| Fazeny-Dörner, B | 1 |
| Veitl, M | 1 |
| Wenzel, C | 1 |
| Brodowicz, T | 1 |
| Zielinski, C | 1 |
| Muhm, M | 1 |
| Vogelsang, H | 1 |
| Marosi, C | 1 |
| Shepherd, FA | 1 |
| Evans, WK | 1 |
| Goss, PE | 1 |
| Latreille, J | 1 |
| Logan, D | 1 |
| Maroun, J | 1 |
| Stewart, D | 1 |
| Warner, E | 1 |
| Paul, K | 1 |
| Scher, CS | 1 |
| Amar, D | 1 |
| McDowall, RH | 1 |
| Barst, SM | 1 |
| Falkson, G | 1 |
| Chasen, MR | 1 |
| Falkson, HC | 1 |
| Cantwell, BM | 1 |
| Carmichael, J | 1 |
| Mannix, KA | 1 |
| Harris, AL | 1 |
| Green, JA | 1 |
| Watkin, SW | 1 |
| Hammond, P | 1 |
| Griggs, J | 1 |
| Challoner, T | 1 |
| Chetiyawardana, SD | 1 |
| Joshi, RC | 1 |
| Woodroffe, CM | 1 |
| Wiltshaw, E | 1 |
| Westbury, G | 1 |
| Harmer, C | 1 |
| McKinna, A | 1 |
| Fisher, C | 1 |
| Pearcey, R | 1 |
| Calvert, R | 1 |
| Mehta, A | 1 |
| Einhorn, LH | 1 |
| Marti, C | 1 |
| Kroner, T | 1 |
| Remagen, W | 1 |
| Berchtold, W | 1 |
| Cserhati, M | 1 |
| Varini, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sleep in Pediatric Hematopoietic Stem Cell Transplant Patients[NCT04106089] | 50 participants (Actual) | Interventional | 2019-11-18 | Completed | |||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471] | Phase 2 | 44 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifosfamide and Emesis
| Article | Year |
|---|---|
[Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
29 trials available for ifosfamide and Emesis
| Article | Year |
|---|---|
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipsych | 2018 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin | 2014 |
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration S | 2010 |
[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2009 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Co | 2011 |
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem | 2002 |
Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2003 |
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2004 |
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2004 |
[Side-effects of polychemotherapy in metastatic testicular neoplasms (author's transl)].
Topics: Adult; Alopecia; Anemia; Bleomycin; Ceruletide; Cisplatin; Constipation; Cyclophosphamide; Drug Ther | 1982 |
Use and safety of high-dose ifosfamide.
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc | 1982 |
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carcinoma, Small Cel | 1993 |
A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children.
Topics: Adolescent; Antiemetics; Chi-Square Distribution; Child; Child, Preschool; Chlorpromazine; Dexametha | 1995 |
Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Female; Hu | 1994 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1993 |
The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug The | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Carci | 1997 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro | 1997 |
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineo | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; | 1998 |
Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC).
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1998 |
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic | 2000 |
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2001 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi | 2001 |
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
25 other studies available for ifosfamide and Emesis
| Article | Year |
|---|---|
Unexpected vomiting in a woman contemplating a second course of chemotherapy for carcinosarcoma of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; F | 2008 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Ci | 2009 |
Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide.
Topics: Adolescent; Adolescent Behavior; Antineoplastic Agents; Attitude to Health; Child; Child Behavior; C | 2010 |
Hypersensitivity pneumonitis associated with the use of trofosfamide.
Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro | 2004 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati | 1982 |
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela | 1983 |
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans; | 1982 |
Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrimeprazine; Neoplasm | 1980 |
Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents.
Topics: Animals; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; | 1994 |
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Hemorrhage; Huma | 1996 |
[Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Huma | 1997 |
The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisp | 1997 |
Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Human | 2002 |
Report on carcinogenesis bioassay of isophosphamide.
Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma | 1978 |
Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma | 1992 |
Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Female; Hum | 1992 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small | 1990 |
Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; H | 1989 |
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; Imidazoles; M | 1989 |
Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1989 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma.
Topics: Female; Half-Life; Humans; Ifosfamide; Uterine Cervical Neoplasms; Vomiting | 1988 |
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn | 1986 |
High-dose ifosfamide in advanced osteosarcoma.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Humans; Ifosfamide; Nausea; Osteosarcoma; Prospective Studi | 1985 |